Compounded tirzepatide vs brand Mounjaro: what is actually different

Compounded tirzepatide costs a quarter of brand Mounjaro or Zepbound and telehealth services like Ro, Henry Meds, Mochi, and LifeMD have moved massive volume through it. The question people search for, over and over, is "is it the same drug?" The answer is more nuanced than yes or no. Here is what is actually different and when the difference matters.

The regulatory shape

Brand Mounjaro is manufactured by Eli Lilly. FDA-approved for type 2 diabetes. Every pen is produced in a facility that complies with current Good Manufacturing Practice (cGMP) rules, with lot-by-lot release testing, continuous cold-chain from fill to pharmacy, and tracked distribution.

Compounded tirzepatide is prepared by a 503A pharmacy. 503A is the FDA category for traditional compounding pharmacies that make customized medications for specific patients. Under standard FDA rules, 503A pharmacies cannot produce commercial copies of an FDA-approved drug. There is an exception: when the FDA-approved drug is on the official shortage list.

Tirzepatide was on the FDA shortage list from late 2022 until October 2024. That window is when telehealth compounding exploded. Lilly's manufacturing capacity caught up, and tirzepatide came off the list. What happened next matters: the FDA issued guidance that 503A pharmacies had to stop new compounding. Some states (and some telehealth services) continued compounding anyway under other legal theories. Court cases are ongoing through 2026.

As of April 2026, compounded tirzepatide is in a regulatory gray zone in the US. It is widely available; the FDA has not universally shut it down; but the legal ground is unstable. This matters for you as a buyer because the pharmacy you are buying from today may not be operating the same way in six months.

What is actually in the vial

The active pharmaceutical ingredient (API) in both brand Mounjaro and a legitimate compounded product is tirzepatide. The molecule is identical. The synthesis route can differ (brand uses its own process; 503A compounds typically source API from FDA-registered API manufacturers, some domestic, some imported).

Where they start to diverge:

Concentration: brand pens are fixed 2.5, 5, 7.5, 10, 12.5, 15 mg per 0.5 mL dose. Compounded products are typically multi-dose vials at 10 mg/mL or 20 mg/mL, so you can draw 2.5 to 15 mg per weekly dose from one vial.

Excipients: brand uses a specific formulation with sodium chloride, sodium phosphate buffer, a small amount of L-histidine, and water for injection. Compounded products sometimes substitute different buffers (citrate is common) which can slightly affect stability. A few compounding pharmacies have used B12 cyanocobalamin as an additive; this is marketed as "enhanced" but has no proven clinical benefit and introduces a trace contaminant.

Preservatives: brand pens are single-use preservative-free. Multi-dose compounded vials typically contain benzyl alcohol as a preservative. For most adults this is fine; for pregnant women and young children it is a flag.

Sterility testing: brand lots undergo USP <71> sterility testing. 503A compounds are required to follow USP <797> sterile compounding standards but the testing rigor varies across pharmacies. This is the single biggest quality variable across compounding sources.

The quality range across 503A pharmacies

This is the part where compounded tirzepatide stops being a single thing. The range is enormous.

Well-run 503A pharmacies:

• Test every API lot for identity, purity, and potency
• Perform USP <71> sterility testing on every compounded lot
• Maintain continuous cold-chain from API receipt to patient shipment
• Publish certificates of analysis on request
• Are inspected by state pharmacy boards and the FDA

Poorly-run 503A pharmacies:

• Source API from unverified overseas vendors
• Skip sterility testing or perform it only on initial qualification lots
• Mix in un-validated excipients
• Store product at ambient or poorly-monitored temperatures
• Have faced warning letters or state board action in the past 24 months

The gap between a top-tier 503A and a marginal one is larger than the gap between a top-tier 503A and brand Mounjaro. Your pharmacy is the variable that matters most.

How to tell which you are getting

Questions to ask the telehealth service before you buy:

1. What pharmacy are you using? If they cannot name it, do not buy. 2. Is that pharmacy inspected and registered with the state board in my state and with the FDA? The answer should include a registration number. 3. Is the product sterility-tested per USP <71>? Can I see a recent COA? Yes, and yes, is the only acceptable answer. 4. What is the cold-chain SOP from pharmacy to my door? Real answer names a shipping carrier, specific packaging (insulated box with gel packs), and a transit-time guarantee. 5. Is there a preservative? If yes, what? Benzyl alcohol is standard. Any answer that is "none" for a multi-dose vial is a red flag.

If the telehealth service does not know the answers, they are a marketing layer on top of a pharmacy they have not vetted. Do not buy.

When compounded is the right choice

• Cost is the hard constraint and brand is out of reach even with insurance
• Your pharmacy is well-vetted (via the questions above, or via Panya's rubric)
• You can do the reconstitution math correctly

When brand is the right choice

• You are in a country (or US state) where compounded is not legally stable
• You want the simplest possible patient experience (pre-measured pen, no math)
• Your insurance covers it and your out-of-pocket is comparable

The Panya take

We include several compounded-tirzepatide telehealth services in our vendor roster (Henry Meds, Mochi, LifeMD, Ro) because some of them score well on our 11-signal rubric, particularly on identity, COA, and response time. A few others we have silently filtered because their pharmacy partners did not respond to sterility-testing questions. We do not name those filtered services publicly; the filter is here with the documented public failures and bucketed counts for the redacted rest.

If you are US-based and want a match between brand, compounded, or a specific pharmacy, take the quiz and we will name the one that fits your profile. We earn a flat referral rate regardless of which you pick.

---

Citations: FDA drug shortage list, tirzepatide removal October 2024; Outsourcing Facility Association and Alliance for Pharmacy Compounding position statements on 503A compounding of GLP-1s; USP <797> Pharmaceutical Compounding — Sterile Preparations; FDA guidance "Compounded Drugs Under Section 503A of the FD&C Act"; Eli Lilly prescribing information for Mounjaro.